Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Davis, Andrew A.
Chae, Young Kwang
Agte, Sarita
Pan, Alan
Mohindra, Nisha
Villaflor, Victoria
Raparia, Kirtee
Giles, Francis J.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-658
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
658
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
    Chae, Young Kwang
    Davis, Andrew A.
    Raparia, Kirtee
    Agte, Sarita
    Pan, Alan
    Mohindra, Nisha
    Villaflor, Victoria
    Giles, Francis
    CLINICAL LUNG CANCER, 2019, 20 (02) : 88 - +
  • [2] Association of circulating tumor DNA (ctDNA) tumor mutational burden (TMB) with DNA repair mutations and response to anti-AD 1/PD-L1 therapy in non-small cell lung cancer (NSCLC).
    Davis, Andrew A.
    Chae, Young Kwang
    Agte, Sarita
    Pan, Alan
    Iams, Wade Thomas
    Cruz, Marcelo Rocha De Sousa
    Mohindra, Nisha Anjali
    Villaflor, Victoria Meucci
    Giles, Francis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Su, Chaoyue
    Wang, Hui
    Liu, Yunru
    Guo, Qiaoru
    Zhang, Lingling
    Li, Jiajun
    Zhou, Wenmin
    Yan, Yanyan
    Zhou, Xinke
    Zhang, Jianye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
  • [5] Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
    Shah, Shalin
    Wood, Kevin
    Brisson, Ryan
    Karrison, Theodore
    Hensing, Thomas
    Luke, Jason J.
    Patel, Jyoti D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S310 - S310
  • [6] PD-L1, Tumor Mutational Burden (TMB) and Intracranial Outcomes in Patients with Non -Small Cell Lung Cancer (NSCLC) and Brain Metastases
    Adib, E.
    Nassar, A. H.
    Kwiatkowski, D. J.
    Aizer, A. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E213 - E213
  • [7] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
    Wan, Renping
    Zhang, Xiaoni
    Qu, Hongyue
    Li, Hui
    Li, Yingmei
    Xu, Mingyan
    Xiao, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
    Kim, H.
    Kwon, H. J. K.
    Kim, E. S. K.
    Han, Y. B.
    Lee, J.
    Kim, S. H.
    Kim, Y. J.
    Lee, J.
    Chung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S470 - S470
  • [9] Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
    Nishioka, Naoya
    Uchino, Junji
    Hirai, Soichi
    Katayama, Yuki
    Yoshimura, Akihiro
    Okura, Naoko
    Tanimura, Keiko
    Harita, Sachi
    Imabayashi, Tatsuya
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Takayama, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (04)
  • [10] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
12345